Table 1.
Cohort 1 characteristics at baseline and during COVID-19 treatment of 13 patients treated with prebiotic inulin for moderate severity COVID-19
| Characteristics | n (proportion) |
| Age (yr, median/IQR) | 58 (50–64) |
| Sex | |
| Male | 6 (46%) |
| Female | 7 (54%) |
| Race | |
| White | 9 (69%) |
| Black | 3 (23%) |
| Asian | 1 (8%) |
| Ethnicity | |
| Hispanic | 6 (46%) |
| Non-Hispanic | 7 (54%) |
| Days hospitalized with COVID-19 (median/IQR) | 5 (3–12) |
| COVID-19 treatmentsa | |
| Supplemental oxygen | 13 (100%) |
| Steroids | 3 (23%) |
| Remdesivir | 1 (8%) |
| Antibioticsb | |
| Any antibiotic | 13 (100%) |
| Ceftriaxone | 8 (62%) |
| Piperacillin-tazobactam | 5 (38%) |
| Doxycycline | 3 (23%) |
| Azithromycin | 4 (31%) |
| Vancomycin | 4 (31%) |
| Discharge on supplemental oxygen | 4 (31%) |
| Psychotropic medications | |
| Selective serotonin reuptake inhibitor | 0 (0%) |
| Tricyclic antidepressant | 0 (0%) |
| Serotonin-norepinephrine reuptake inhibitor (duloxetine) | 1 (8%) |
COVID-19, coronavirus-19 disease; IQR, interquartile relationship.
a
One subject received both convalescent plasma and ivermectin; a different subject received hydroxychloroquine.
b
Antibiotics received within 24 hours before enrollment. Ten of 13 patients received multiple antibiotics. In addition to the antibiotics listed, 1 subject received levofloxacin and another received cephalexin.